As you know, multiple myeloma is a challenging disease to treat, given the potential for relapse and resistance to therapy. It can also be an emotional and physical rollercoaster for both patients and their loved ones. That’s why we’re pursuing advances for patients through a comprehensive research program called MagnetisMM.

Part 2 of MagnetisMM-6 is a phase 3, randomized, open-label clinical trial evaluating whether the study drug combination,

  • elranatamab (E) + daratumumab (D) + lenalidomide (R) = EDR combination

can provide clinical benefit compared to a standard of care combination,

  • daratumumab (D) + bortezomib (V) + lenalidomide (R) + dexamethasone (d) = D-VRd combination

in stem cell transplant-ineligible participants with newly diagnosed multiple myeloma.

Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody, that enables targeted T-cell-mediated cytotoxicity by binding one epitope to CD3-expressing T-cells and the second epitope to BCMA-expressing multiple myeloma cells.

Elranatamab is being studied in multiple clinical trials both as a monotherapy and in combination with approved therapies, for treatment of adult patients with multiple myeloma.

News about Elranatamab

Click below to view a video on BCMA as a target for multiple myeloma treatment.

Study Population

Part 2 of this study is looking for about [870] adult participants (18+) who:

  • Have a diagnosis of multiple myeloma as defined according to International Myeloma Working Group (IMWG) criteria
  • Have newly diagnosed multiple myeloma and are stem cell transplant-ineligible, defined by age or comorbidities impacting the possibility of transplant
  • Have adequate bone marrow, hepatic, and renal function
  • Have no other surgical (including major surgery within 14 days prior to enrollment), medical or psychiatric conditions including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study

There are additional criteria listed in the study protocol (C1071006).

Study duration

Participation in Part 2 of the MagnetisMM-6 study will last until it is necessary for participants to discontinue for whatever reason. During this time, participants will be asked to attend regular study visits. This includes hospitalization and several clinic visits in the initial 14-day (Cycle 0) dose period, for participants assigned to the EDR combination only.

Study duration

Participation in Part 2 of the MagnetisMM-6 study will last until it is necessary for participants to discontinue for whatever reason. During this time, participants will be asked to attend regular study visits. This includes hospitalization and several clinic visits in the initial 14-day (Cycle 0) dose period, for participants assigned to the EDR combination only.

Is this page helpful?

Together we can make a difference

People are often introduced to the world of clinical trials through conversations with their healthcare provider. As with anything new, there may be a number of questions, concerns, or misconceptions. Being their trusted healthcare provider, we appreciate you taking the time to have an open discussion with patients and their loved ones who may be interested in contributing to research.

Clinical trials may be an option that your patients will want to consider. While no benefit is guaranteed from an investigational medicine, your patients who participate in a clinical trial will contribute to the process of developing a potential new therapy.

If you would like more study-specific information to help inform conversations with potential participants, please let us know. Should any of your patients take part in Part 2 of the MagnetisMM-6 clinical trial, they will remain under your medical care for all non-study-related needs and will continue to receive any benefits to which they are entitled.

To keep the line of communication open between you and your patients, feel free to follow up with them to see if they randomized into this clinical trial and to keep in touch with them throughout their study journey.

Pfizer will give MagnetisMM-6 Part 2 participants the option to access certain individual data, approximately 12 months after study completion. This allows participants to share data with their healthcare provider after their study participation concludes.